Quarterly ResultMay 14, 2026, 02:01 PM
Monopar Q1 Net Loss $3.9M; ALXN1840 NDA on Track for Mid-2026
AI Summary
Monopar Therapeutics announced its first quarter 2026 financial results, reporting a net loss of $3.9 million, or $0.46 per share, compared to a net loss of $2.6 million in Q1 2025. The company maintained a strong cash position of $137.5 million as of March 31, 2026, which is expected to fund operations through December 31, 2027. Additionally, Monopar confirmed that the New Drug Application (NDA) submission for ALXN1840 for Wilson Disease remains on track for mid-2026, following positive Phase 3 FoCus trial data presentations at the AAN Annual Meeting and upcoming presentations at EAN and EASL Congresses.
Key Highlights
- ALXN1840 NDA submission for Wilson Disease remains on track for mid-2026.
- Cash, cash equivalents and investments totaled $137.5 million as of March 31, 2026.
- Funds are expected to support operations at least through December 31, 2027.
- Net loss for Q1 2026 was $3.9 million, or $0.46 per share, compared to $2.6 million in Q1 2025.
- R&D expenses increased by $1.84 million to $3.49 million in Q1 2026.
- G&A expenses increased by $0.16 million to $1.74 million in Q1 2026.
- Interest income rose to $1.33 million in Q1 2026 from $0.60 million in Q1 2025.
- New analyses from the Phase 3 FoCus trial of ALXN1840 presented at AAN 2026.